Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Inclusion Criteria

• •1. Diagnosis of myelodysplastic disorders, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoproliferative disorders (Non-Hodgkin Lymphoma, Hairy Cell Leukemia, Chronic Lymphocytic Leukemia and Hodgkins Disease) or Renal Cell Carcinoma.
• •2. Conditions that increase treatment related mortality (need one or more to be eligible):
• •1. Greater to or equal to 50 years of age.
• •2. EF of less than 45%
• •3. DLCO less than 50% of FEV1 50-75% of predicted value.
• •4. Diabetes Mellitus
• •5. Renal Insufficiency (but creatine clearance not less than 25ml/min).
• •6. Prior recent history of systemic fungal infection.
• •7. 3rd or greater remission of AML or ALL
• •8. More than 1 year of diagnosis (CML or Myeloma patients)
• •9. Multiple types of treatment regimens. (equal to or more than 3)
• •10. Prior autologous or allogeneic stem cell transplantation.
• •11. Significant grade III or IV neurologic or hepatic toxicity from previous treatment.
• •12. No matched sibling donor.
• •3. Available healthy donor without any contraindications for donation. 5/6 or 6/6 related donor. 5/6 or 6/6 unrelated donor (molecular typing for DRB1)
• •4. Patient and/or responsible person able to understand consent.
• •5. Age between birth and 70 years.
• •6. For women of childbearing potential, negative pregnancy test.